Platelet reactivity in patients with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose of clopidogrel: Results of the Effect of Platelet Inhibition According to Clopidogrel Dose in Patients with Chronic Kidney Disease (PIANO-2 CKD) randomized study

American Heart Journal

Volumn 162, Issue 6, 2011, Pages 1018-1025

  Woo, Jong Shin ^a   Kim, Weon ^a   Lee, Sul Ra ^a   Jung, Kyung Hwan ^a   Kim, Woo Shik ^a   Lew, Jae Hwan ^b   Lee, Tae Won ^a   Lim, Chun Kyu ^a  

^a Kyung Hee University Hospital   (South Korea)

^b Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; CILOSTAZOL; CLOPIDOGREL; PADGEM PROTEIN; PURINERGIC P2Y12 RECEPTOR;

ADJUVANT THERAPY; ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; HUMAN CELL; KIDNEY FUNCTION; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT RESPONSE;

ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; CHRONIC DISEASE; CORONARY ARTERY DISEASE; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RENAL DIALYSIS; TETRAZOLES; TICLOPIDINE;

EID: 82555170248     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.09.003     Document Type: Article

References (20)

1. P.J. Best, R. Lennon, and H.H. Ting The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions J Am Coll Cardiol 39 2002 1113 1119 (Pubitemid 34267412)
2. P.J. Best, S.R. Steinhubl, and P.B. Berger The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial Am Heart J 155 2008 687 693
3. S.H. Park, W. Kim, and C.S. Park A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure Am J Cardiol 104 2009 1292 1295
4. D.J. Angiolillo, E. Bernardo, and D. Capodanno Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy J Am Coll Cardiol 55 2010 1139 1146
5. S. Goto Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding Atheroscler Suppl 6 2005 3 11 (Pubitemid 43263084)
6. T.A. Meadows, and D.L. Bhatt Clinical aspects of platelet inhibitors and thrombus formation Circ Res 100 2007 1261 1275 (Pubitemid 46742917)
7. S.W. Lee, S.W. Park, and M.K. Hong Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis J Am Coll Cardiol 46 2005 1833 1837
8. D.J. Angiolillo, S.B. Shoemaker, and B. Desai Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study Circulation 115 2007 708 716 (Pubitemid 46294761)
9. Y.H. Jeong, S.W. Lee, and B.R. Choi Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study J Am Coll Cardiol 53 2009 1101 1109
10. M.J. Price, S. Endemann, and R.R. Gollapudi Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000 (Pubitemid 351844676)
11. T. Cuisset, C. Frere, and P.J. Moro Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after acute coronary syndrome Thromb Res 126 2010 e400 2
12. G. Soslau, I. Brodsky, and B. Putatunda Selective reduction of serotonin storage and ATP release in chronic renal failure patients platelets Am J Hematol 35 1990 171 178 (Pubitemid 20359076)
13. J. Malyszko, J.S. Malyszko, and D. Pawlak Hemostasis, platelet function and serotonin in acute and chronic renal failure Thromb Res 83 1996 351 361 (Pubitemid 26284109)
14. D. Mezzano, R. Tagle, and O. Panes Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis Thromb Haemost 76 1996 312 321 (Pubitemid 26373520)
15. D. Mezzano, R. Tagle, and E. Pais Endothelial cell markers in chronic uremia: relationship with hemostatic defects and severity of renal failure Thromb Res 88 1997 465 472 (Pubitemid 28219053)
16. I. Iakovou, T. Schmidt, and E. Bonizzoni Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 293 2005 2126 2130 (Pubitemid 40617065)
17. F. Latif, N.S. Kleiman, and D.J. Cohen In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry JACC Cardiovasc Interv 2 2009 37 45
18. N. von Beckerath, A. Kastrati, and A. Wieczorek A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days Eur Heart J 28 2007 1814 1819 (Pubitemid 47236637)
19. M.J. Price, P.B. Berger, and P.S. Teirstein Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial JAMA 305 2011 1097 1105
20. D.J. Angiolillo, P. Capranzano, and S. Goto A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study Eur Heart J 29 2008 2202 2211